Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Author:

Shah Nirav N.1,Ahn Kwang Woo23,Litovich Carlos3,Fenske Timothy S.4,Ahmed Sairah5,Battiwalla Minoo6,Bejanyan Nelli7,Dahi Parastoo B.8,Bolaños-Meade Javier9,Chen Andy I.10,Ciurea Stefan O.5,Bachanova Veronika11,DeFilipp Zachariah12,Epperla Narendranath13,Farhadfar Nosha14,Herrera Alex F.15,Haverkos Bradley M.16,Holmberg Leona17,Hossain Nasheed M.18,Kharfan-Dabaja Mohamed A.19,Kenkre Vaishalee P.20,Lazarus Hillard M.21,Murthy Hemant S.14,Nishihori Taiga22,Rezvani Andrew R.18,D’Souza Anita3,Savani Bipin N.23,Ulrickson Matthew L.24,Waller Edmund K.25,Sureda Anna26,Smith Sonali M.27,Hamadani Mehdi3

Affiliation:

1. Division of Hematology and Oncology,

2. Division of Biostatistics, Institute for Health and Society,

3. Center for International Blood and Marrow Transplant Research, Department of Medicine, and

4. Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;

5. MD Anderson Cancer Center, University of Texas, Houston, TX;

6. Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;

7. Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN;

8. Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

9. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD;

10. Oregon Health and Science University, Portland, OR;

11. Bone and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN;

12. Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;

13. Division of Hematology, The James Cancer Center and Solove Research Institute, The Ohio State University, Columbus, OH;

14. University of Florida, Gainesville, FL;

15. City of Hope, Duarte, CA;

16. University of Colorado Hospital, Aurora, CO;

17. Fred Hutchinson Cancer Research Center, Seattle, WA;

18. Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA;

19. Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL;

20. University of Wisconsin, Madison, WI;

21. Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH;

22. Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL;

23. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;

24. Banner MD Anderson Cancer Center, Gilbert, AZ;

25. Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;

26. Hematology Department, Institut Català d'Oncologia–Hospitalet, Barcelona, Spain; and

27. Section of Hematology/Oncology, The University of Chicago, Chicago, IL

Abstract

Key Points There was no difference in overall survival after allogeneic transplant between patients aged 55-64 years and patients ≥65 years. Age alone should not be a determinant for allogeneic transplant eligibility among older non-Hodgkin lymphoma patients.

Publisher

American Society of Hematology

Subject

Hematology

Reference27 articles.

1. Current use and trends in hematopoietic cell transplantation in the United States;D’Souza;Biol Blood Marrow Transplant,2017

2. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies;Sorror;JAMA,2011

3. Outcome of patients 65 years and older with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age;Atallah;Blood,2015

4. National Coverage Determination (NCD) for Stem Cell Transplantation. (Formerly 110.8.1) (110.23), Centers of Medicare and Medicaid Services. Available at: https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/. Accessed 20 January 2018.

5. SEER Cancer Statistics Review (CSR), 1975-2014. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Available at: http://seer.cancer.gov/csr/1975_2014/. Accessed 18 December 2017.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3